HK Stock Market Move | IMMUNEONCO-B(01541) increased by over 7% against the market trend, IMM2510/AXN-2510 received FDA approval for IND application.

IMMUNEONCO-B(01541) rose more than 7% against the market, with an increase of 7.22% as of the end of the reporting period, reaching 13.06 Hong Kong dollars with a trading volume of 137.818 million Hong Kong dollars. On the news front, IMMUNEONCO-B announced that the company, together with Instil, happily announced that Instil has received approval for the new drug clinical trial (IND) of IMM2510/AXN-2510 from the United States Food and Drug Administration (FDA). Instil is expected to initiate a Phase 1b/2 trial of IMM2510/AXN-2510 as a monotherapy for patients with recurrent/refractory solid tumors by the end of 2025. The trial aims to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of IMM2510/AXN-2510 in patients with solid tumors. In addition, data from the Phase 2 study of IMM2510/AXN-2510 in combination with chemotherapy for first-line non-small cell lung cancer (NSCLC) being conducted in China is expected to be announced by the company in the second half of 2025.